Innovative immunotherapy clinical trial underway at The University of Kansas Cancer Center

A novel immunotherapy clinical trial underway now at The University of Kansas Cancer Center has enrolled the first patients in the world to receive what many doctors and researchers believe is the future of cancer treatment. The trial turns the patient's own body into a cancer fighting machine. T-cells taken from the patient are modified and multiplied and then given back to the patient through an infusion. The patients in the current trial suffer diffuse large B cell non-Hodgkin's lymphoma -- the most common type of lymphoma. CAR T-cell therapy has proven successful in fighting blood cancers and doctors believe it could be adapted to target other cancers like breast and colon.

"Think of 'Pac-Man'," Joseph McGuirk, DO, and medical director of the Blood and Marrow Transplant Program at The University of Kansas Cancer Center said. "The patient's re-engineered cells are trained to chase down the cancer and destroy it."

Patients enrolled in the trial include a 26-year-old mother of two from Atchison, Kan. and a businessman from Australia who relocated his family temporarily for a chance at this cancer trial. NCI Designation makes this trial possible.

SOURCE The University of Kansas Cancer Center

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.

or

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Persistent COVID-19 in the intestines may drive inflammation in cancer patients